AMB Guidelines: COVID-19

Ferreira, Lincoln Lopes; Sampaio, Diogo Leite; Chagas, Antônio Carlos Palandri; Guimarães, Hélio Penna; Hajjar, Ludhmila Abrahão; Lobo, Suzana Margareth; Abdo, Carmita Helena Najjar; Bonamigo-Filho, José Luiz; Bacha, Hélio Arthur; Moura, Robson Freitas de; Bernardo, Wanderley Marques

doi:10.1590/1806-9282.66.9.1179

Cited by 1 publication

(5 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From 2226 citations, the reviewers screened 51 full texts and identified 32 eligible CPGs . We excluded 19 CPGs (eFigure in Supplement 1).…”

Section: Resultsmentioning

confidence: 99%

“… Of the 32 included CPGs, 3 (9.4%) reported on pharmacologic treatments for critically ill patients specifically, and the remainder reported on treatments for hospitalized patients with COVID-19. Fifteen CPGs (46.9%) were international and 17 (53.1%) were national . Most CPGs (25 [78.1%]) had sponsorship from 1 or more national societies, and few CPGs (3 [9.4%]) had sponsorship from government, nongovernment, or not-for-profit agencies (4 [12.5%]) .…”

Section: Resultsmentioning

confidence: 99%

“…Eighteen CPGs (56.3%) explicitly disclosed funding information . Twenty CPGs (62.5%) included multidisciplinary guideline panels, and 5 guideline panels (15.6%) included a methodologist.…”

Section: Resultsmentioning

confidence: 99%

“…We identified 12 CPGs (37.5%) with high adherence (score of 4 or 5) to the NAM standard to disclose actual or potential financial COIs and report how COIs were incorporated or managed in the CPG development process. Eight CPGs (25.0%) had intermediate adherence (score of 3) and 12 CPGs (37.5%) had low adherence (score of 1 or 2) to this NAM standard.…”

Section: Resultsmentioning

confidence: 99%

“…We excluded 19 CPGs (eFigure in Supplement 1). [45][46][47][48][49][50][51][52][53][54][55][56][57][58][59][60][61][62][63] Of the 32 included CPGs, 3 (9.4%) 15,38,40 reported on pharmacologic treatments for critically ill patients specifically, and the remainder reported on treatments for hospitalized patients with COVID-19. Fifteen CPGs (46.9%) were international 15,16,20,21,23,24,27,[31][32][33][34]36,38,43,44 and 17 (53.1%) were national.…”

Section: Cpg Identification and Quality Assessmentmentioning

confidence: 99%

See 4 more Smart Citations

Adherence of Clinical Practice Guidelines for Pharmacologic Treatments of Hospitalized Patients With COVID-19 to Trustworthy Standards

et al. 2021

View full text Add to dashboard Cite

Key Points Question Do clinical practice guidelines (CPGs) that report on pharmacologic treatments of hospitalized patients with COVID-19 meet the National Academy of Medicine standards for trustworthiness? Findings In this systematic review of 32 CPGs of predominantly low quality, few reported funding sources or conflicts of interest, included a methodologist, described a search strategy or study selection process, or synthesized evidence. Although 14 CPGs (43.8%) made recommendations or suggestions for or against treatments, they infrequently rated the confidence in the quality of the evidence (6 [18.8%]), described potential benefits and harms (6 [18.8%]), or graded the strength of recommendations (5 [15.6%]). Meaning The findings of this study suggest that few COVID-19 CPGs meet National Academy of Medicine standards for trustworthy guidelines.

show abstract

“…From 2226 citations, the reviewers screened 51 full texts and identified 32 eligible CPGs . We excluded 19 CPGs (eFigure in Supplement 1).…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

“…Eighteen CPGs (56.3%) explicitly disclosed funding information . Twenty CPGs (62.5%) included multidisciplinary guideline panels, and 5 guideline panels (15.6%) included a methodologist.…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%